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Abstract
Background:  Disseminated mycobacterium avium complex (MAC) occurs mainly in
immunocompromised hosts, which is associated with abnormal cellular immunity.
Case presentation: A 26-year-old pregnant woman presented with fever and general weakness.
Miliary lung nodules were noted on chest X-ray. Under the impression of miliary tuberculosis, anti-
tuberculosis medication was administered. However, the patient was not improved. Further work-
up demonstrated MAC in the sputum and placenta. The patient was treated successfully with
clarithromycin-based combination regimen.
Conclusion: This appears to be the first case of disseminated MAC in an otherwise healthy
pregnant woman. Clinicians should be alert for the diagnosis of MAC infection in diverse clinical
conditions.
Background
Mycobacterium avium complex (MAC) causes three major
clinical disease entities: pulmonary disease, disseminated
MAC disease, and cervical lymphadenitis [1,2].
MAC has been found to colonize natural water, soil,
indoor water systems, and hot tubs, and it can be isolated
from the sputum of apparently healthy individuals [3,4].
Clinically, MAC pulmonary disease is more frequently
seen in patients with underlying lung disease such as
bronchiectasis, pneumoconiosis, and prior tuberclulosis,
but approximately 24 to 59 percent of them occur in
immunocompetent persons without evident predisposing
factors [2,5].
In comparison, disseminated MAC disease has been
mainly noted in immunocompromised hosts with
impaired cellular immunity [1]. Recently, we experienced
an interesting case of disseminated MAC disease, which
occurred in an otherwise healthy pregnant woman. Preg-
nancy might affect on the patient's immune status.
Herein, we report the unusual case with the review of pre-
viously published literatures.
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Case presentation
A 26-year-old pregnant woman presented to the Division
of Infectious Diseases at Korea university Guro hospital,
Seoul, Republic of Korea (ROK) with history of fever and
abdominal pain for a week. She was a healthy hepatitis B
virus (HBV) carrier that was vertically transmitted from
her mother. The patient was in the 13th week of her first
pregnancy, and she did not take any medicine at all. The
patient was admitted for work-up of her febrile condition.
On admission, her vital signs were body temperature
38.1°C, blood pressure 100/60 mmHg, and pulse rate 86
times/minute. She complained of generalized weakness,
loose stool, night sweating, and dry cough. On physical
examination, mild right upper quadrant tenderness and
decreased breathing sound on the right lower lung field
were noted. Initial laboratory investigations showed mild
anemia, with a hemoglobin level of 10.9 g/dL and a plate-
let count of 232 × 103 platelets/mm3. White blood cell
(WBC) count was not elevated with 6,100 cells/mm3.
Aminotransferase levels were elevated with levels of 127/
117 IU/L in AST/ALT respectively. Alkaline phosphatase
level (207 IU/L) was also increased. Serologic tests for
HIV, Hepatitis C virus (HCV) and hepatitis A virus (HAV)
were negative. Activity of HBV was not increased: hepatitis
e antigen (-), hepatitis e antibody (+), HBV DNA (1.0 pg/
mL). The patient's chest X-ray showed numerous tiny
nodular opacities on both lungs, and high-resolution
computed tomography of the chest demonstrated numer-
ous randomly distributed nodules (Fig. 1A). Tuberculin
test showed anergy. Those findings were compatible with
miliary tuberculosis.
In ROK, tuberculosis is still highly prevalent, so the
patient was initially suspected of having miliary tubercu-
losis in the lung. Anti-tuberculosis medication was started
with isoniazid (300 mg qd), rifampin (600 mg qd),
(A) High resolution computed tomography of lung shows multiple tiny nodules in the entire lung fields and conglomerated  lesions in left lung fields Figure 1
(A) High resolution computed tomography of lung shows multiple tiny nodules in the entire lung fields and conglomerated 
lesions in left lung fields. (B) Many acid fast bacilli were shown on Ziehl-Neelson stain of placenta tissue from the patient.BMC Infectious Diseases 2006, 6:154 http://www.biomedcentral.com/1471-2334/6/154
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ethambutol (1.2 g qd), and pyrazinamide (1.5 g qd). Ami-
notransferase levels were not elevated further during the
course of anti-tuberculosis medication. Sputum induction
with hypertonic saline was performed because the patient
only had intermittent dry cough and scanty sputum. The
sputum study was negative for Mycobacterium on Ziehl-
Neelson stain.
High fever persisted despite anti-tuberculosis medication.
On day 15 of anti-tuberculosis medication, the patient's
condition was aggravated; she suffered from severe dysp-
nea and hyperemesis. Fetal distress was suspected, forcing
us to terminate the pregnancy. Pathologic specimens
obtained from the placenta demonstrated many acid fast
bacilli in Ziehl-Neelson stain (Fig. 1B). However, the
patient was still febrile despite the termination of preg-
nancy and continued anti-tuberculosis medication. The
authors believed that an immunologic response might
have been responsible for the high fever and added oral
steroid (oral prednisone; 1 mg/kg) to the patient's medi-
cation. The patient felt better and was no longer febrile.
The patient was subsequently discharged from the hospi-
tal with those medications.
During outpatient follow-up, the patient complained of
frequent episodes of fever and exertional dyspnea even
though she was taking anti-tuberculosis medication.
Chest X-ray revealed that the pulmonary disease worsened
with multiple nodules in the entire lung. On day 45 of
anti-tuberculosis medication, results from the initial
series of sputum mycobacterial cultures on ogawa
medium were available; Mycobacterium other than tuber-
culosis (MOTT) was demonstrated repeatedly. Result
from placenta was same also. The patient's chest X-ray
showed no improvement since discharge from the hospi-
tal, with persistent multiple tiny nodules in both lung
fields. The medication was changed to clarithromycin
(500 mg bid), rifampin (600 mg qd), ofloxacin (300 mg
bid), and ethambutol (1.2 g qd).
On day 60 of anti-MOTT medication, all the patient's
symptoms were dramatically improved. Chest X-ray was
nearly cleared up, and liver function tests resolved com-
pletely also. On day 105 of anti-MOTT medication, myco-
bacterial speciation culture report from sputum and
placenta specimens revealed Mycobacterium avium intracel-
lurare  with isoniazid, ethambutol, and Para-aminosali-
cylic acid resistance. The drug regimen was adjusted in
accordance with results from the antibiotic susceptibility
test: clarithromycin, rifampin, and ofloxacin. The patient
is on the 10 months of the new drug regimen with contin-
uous improvement of her condition. Follow-up HIV serol-
ogy was negative and the result of tuberculin test was
converted to strong positive (2.5 cm sized induration),
which were performed after 10 month medication (Fig.
2). No specific abnormality was noted on gynecologic
examination, endoscopy, breast and abdominal sono-
gram.
Discussion
We report a rare disseminated MAC case in an otherwise
healthy, pregnant woman; there had been only sporadic
case reports of disseminated MAC disease among immu-
nocompetent adults [6-10]. Though the patient in this
case was a HBV carrier, there was no evidence of liver cir-
rhosis on physical examination and abdominal sono-
gram. Platelet count was also normal. Repeated HIV
serology was negative and tuberculin test showed strong
positive reflecting normal cell-mediated immunity. Stud-
ies of malignancy work-up showed no abnormal finding.
Disseminated MAC disease is typically associated with
defective cellular immunity such as hairy cell leukemia,
chronic myelogenous leukemia and AIDS [11]. Tumor
necrosis factor (TNF)-α and IFN-γ are both important in
the defense against mycobacterial disease. Schematically,
stimulated CD4+ T-lymphocytes produce IL-12 and IFN-γ.
These cytokines act on lymphocytes and macrophages to
stimulate the production of IL-2, TNF-α, and reactive oxi-
dative intermediates such as superoxide and nitric oxide
that participate in the host defense against mycobacteria
[12]. Patients with lymphoreticular malignancies or AIDS
are at risk of disseminated MAC infection, usually when
the CD4+ count is <50 µL. In those patients, macrophages
are unable to kill the intracellular mycobacteria largely
because they lack the help of CD4+ T-cells secreting INF-γ
and TNF-α; these cytokines are necessary for the activation
of macrophages.
Alterations of the immune status in the pregnant woman
are necessary to allow mothers to tolerate genetically dif-
ferent fetal tissues during pregnancy. These alterations
lead to impaired cell-mediated immunity with increased
susceptibility to certain infections such as tuberculosis
[13,14]. During pregnancy, the maternal immune system
also shows a relative bias toward T helper (type 2) immu-
nity. Therefore, we presumed that disseminated MAC
infection in this case might be related to pregnancy state,
even though immune-suppressed disease did not exist.
Likewise, cytomegalovirus infection and disseminated
aspergillosis had been reported as opportunistic infec-
tions in the pregnant women [15,16].
Since the mid 1990s, genetic abnormalities are known to
be predisposed to infection by intracellular pathogens
including MAC and other mycobacteria; mutations in the
interferon γ receptor 1 (IFN-γR1) gene and natural resist-
ance-associated macrophage protein (nramp) gene have
been reported [5]. This case however, was not analyzed forBMC Infectious Diseases 2006, 6:154 http://www.biomedcentral.com/1471-2334/6/154
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these genes because no other family member revealed
mycobacterial disease.
As for the diagnosis of disseminated MAC infection,
though blood culture was not taken, positive cultures
were identified from more than one organ (lung and pla-
centa), and the patient showed compatible clinical/labo-
ratory findings. Multi-drug therapy including
clarithromycin or azithromycin is recommended for the
treatment of disseminated MAC patients with AIDS based
on available data [17,18]. In contrast, no standard treat-
ment has been established for HIV-negative patients with
disseminated MAC infection. In this case, we treated the
patient with combination of rifampin, ofloxacin and clar-
ithromycin, and it was effective. We excluded ethambutol
from the treatment regimen according to the in vitro sus-
ceptibility test. Actually, however, the susceptibility test of
MAC has no value in guiding the selection of drugs other
than clarithromycin [19].
In this study, CD4 T cell count was not checked during fol-
low-up period, which was the limitation of this report.
However, the patient was previously healthy and WBC
count was within normal range. The positive conversion
of tuberculin test was checked during treatment period
after therapeutic abortion, therefore we thought those
could be an indirect evidence of intact cellular immunity.
In conclusion, this case highlights a series of problems
associated with MAC disease including delay in diagnosis,
undefined mode of transmission, potential severity of the
disease, and difficulty in treatment. Clinicians should be
alert for the diagnosis of MAC infection in diverse clinical
conditions. Large-scale study is needed in those patients
Tuberculin test was performed after the patient was stabilized with anti-MOTT (mycobacterium other than tuberculosis) med- ication; 2.5 cm sized induration was observed 48–72 hours later Figure 2
Tuberculin test was performed after the patient was stabilized with anti-MOTT (mycobacterium other than tuberculosis) med-
ication; 2.5 cm sized induration was observed 48–72 hours later.Publish with BioMed Central    and   every 
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with disseminated MAC disease, who are immunocompe-
tent and free from underlying lung disease: treatment reg-
imens, treatment duration, virulence factors of MAC, and
host immunity.
Conclusion
We report a rare disseminated MAC case in an otherwise
healthy, pregnant woman. The patient was treated suc-
cessfully with combination of rifampin, ofloxacin and
clarithromycin. Clinicians should be alert for the diagno-
sis of MAC infection in diverse clinical conditions.
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